X0306 4 2020-06-09 0 0001595893 Turning Point Therapeutics, Inc. TPTX 0001772259 Cui Jingrong Jean C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DRIVE, STE. 200 SAN DIEGO CA 92121 1 0 0 0 Common Stock 1001298 D Common Stock 300000 I By The Jean Cui 2020 GRAT Common Stock 2020-06-09 4 S 0 412 63.80 D 549471 I By spouse Common Stock 2020-06-09 4 S 0 1688 64.82 D 547783 I By spouse Common Stock 2020-06-09 4 S 0 4515 65.80 D 543268 I By spouse Common Stock 2020-06-09 4 S 0 2585 66.60 D 540683 I By spouse Common Stock 2020-06-09 4 S 0 300 67.48 D 540383 I By spouse Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. The weighted average sale price for the transaction reported was $63.80, and the range of prices were between $63.25 and $64.20. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $64.82, and the range of prices were between $64.26 and $65.17. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $65.80, and the range of prices were between $65.26 and $66.24. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $66.60, and the range of prices were between $66.27 and $67.18. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $67.48, and the range of prices were between $67.34 and $67.915. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. /s/ Annette North, Attorney-in-Fact 2020-06-10